Propanc Biopharma Publishes Data on PRP and Chemotherapy-Resistant Cells
Propanc says peer-reviewed research found PRP activity against chemotherapy-resistant pancreatic cancer cells. The company says a Phase 1b first-in-human study is planned.
Propanc says peer-reviewed research found PRP activity against chemotherapy-resistant pancreatic cancer cells. The company says a Phase 1b first-in-human study is planned.